Louis Philipson to Quality-Adjusted Life Years
This is a "connection" page, showing publications Louis Philipson has written about Quality-Adjusted Life Years.
Connection Strength
0.077
-
First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists : A Cost-Effectiveness Study. Ann Intern Med. 2022 10; 175(10):1392-1400.
Score: 0.050
-
Cost-effectiveness of MODY genetic testing: translating genomic advances into practical health applications. Diabetes Care. 2014; 37(1):202-9.
Score: 0.027